Related Experiment Video
Updated: Jun 17, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Treatment of multiple sclerosis
Marija Bosnjak-Pasić1, Branka Vidrih, Snjezana Miskov
1University Department of Neurology, Reference Center for Neurovascular Disorders, Ministry of Health and Social Welfare of the Republic of Croatia, Sestre milosrdnice University Hospital, Zagreb, Croatia. marijabosnjakpasic@net.hr
Abstract:
Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system, characterized by multifocal inflammatory destruction of myelin, axonal damage and loss of oligodendrocytes. The disease is carried through two stages: inflammatory and degenerative. The most common form of disease in approximately 85% of the cases is RRMS (relapsing-remitting form). The treatment of MS is devided into: treatment of the acute phase of illness, prevention of new relapses and disease progression, and symptomatic treatment. Most of the changes in treatment of multiple sclerosis and most of the news in recent years concerning new drugs are used in the treatment of progression of the disease and prevention of disease relapses. Some of these drugs are registrated in most Europian countries and USA, and others are in various stages of research.
Insights
Multiple sclerosis (MS) is an autoimmune central nervous system disease. Recent advancements focus on new treatments to prevent relapses and slow disease progression, with some drugs approved and others in research.
Area of Science:
- Neuroimmunology
- Neurology
- Demyelinating diseases
Background:
- Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease affecting the central nervous system.
- It involves multifocal inflammatory destruction of myelin, axonal damage, and oligodendrocyte loss.
- MS progresses through inflammatory and degenerative stages, with relapsing-remitting MS (RRMS) being the most common form (85% of cases).
Purpose of the Study:
- To review current treatment strategies for multiple sclerosis.
- To highlight recent advancements in disease-modifying therapies.
- To discuss the development and registration status of new MS drugs.
Main Methods:
- Literature review of recent studies and drug development in multiple sclerosis.
- Analysis of treatment approaches for acute phases, relapse prevention, and progression management.
- Examination of drug registration in European countries and the USA.
Main Results:
- The majority of recent therapeutic advancements in MS target disease progression and relapse prevention.
- Several new drugs have been registered in major markets like Europe and the USA.
- Other promising treatments are currently in various phases of clinical research and development.
Conclusions:
- Current MS treatment focuses on managing relapses and slowing disease progression with novel therapies.
- The pipeline for new MS drugs is active, with ongoing research and regulatory approvals.
- Continued research is crucial for further improving patient outcomes in multiple sclerosis.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Alzheimer's Disease: Treatment
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:28Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...